00000nam 2200000zi 4500 9.907333 CaOODSP 20250107144057 m o d f cr cn||||||||| 220126e202202##oncd obs f000 0 eng d 9780660417950 CaOODSP eng rda CaOODSP n-cn--- H82-29/3-2022E-PDF Alignment among public formularies in Canada, part 3 : medicines assessed by the common drug review. Ottawa, ON : Patented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, February 2022. ©2022 1 online resource (iii, 21 pages) : colour charts text txt rdacontent computer c rdamedia online resource cr rdacarrier Issued also in French under title: Concordance des listes de médicaments des régimes publics au Canada, partie 3 : médicaments évalués par le programme commun d'évaluation des médicaments. Issued also in HTML format. Includes bibliographical references. "This is the last report in a three-part PMPRB series that explores current overlaps and gaps in Canadian public drug plan formularies"--Executive summary, page ii. Pharmaceutical services insurance Canada Statistics. Drugs Canada Statistics. Pharmaceutical policy Canada. Statistics lcgft Canada. Patented Medicine Prices Review Board, issuing body. Concordance des listes de médicaments des régimes publics au Canada, partie 3 : (CaOODSP)9.907335 PDF 2.60 MB https://publications.gc.ca/collections/collection_2022/cepmb-pmprb/H82-29-3-2022-eng.pdf HTML N/A https://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/formularies-part3-medicines-assessed.html